An international scale study published in a journal Nature Medicine brings crucial news to the world of health. The study revealed that more than a third, or around 38 percent of new cancer cases worldwide, could have been prevented by controlling common risk factors such as smoking, infections and alcohol consumption.
Based on data released on Friday (6/2/2026), of the total of 18.7 million new cancer cases globally in 2022, 7.1 million cases were closely related to causes that could be modified or managed. Gastric, lung and cervical cancer are recorded as contributing almost half of the total cases that could have been avoided.
Main Risk Factors: Smoking and Infections This research, which covers 36 types of cancer in 185 countries, places smoking tobacco as the largest contributor, responsible for 15 percent of preventable cases. In second place, infection accounted for 10 percent of cases, followed by alcohol consumption by 3 percent.
- In Men: Smoking is the dominant risk factor worldwide, causing almost 25 percent of all avoidable cases.
- In Women: Infectious factors, such as Human Papillomavirus (HPV), poses a serious threat, especially in low-income regions such as Sub-Saharan Africa, where cervical cancer remains very common.
Differences in Challenges in Different Regions The results of this study highlight the existence of geographic disparities in cancer drivers. In high-income areas such as Europe and North America, smoking is the main cause of cancer cases in men and women. On the other hand, in Asia, Africa and South America, infection is the second main cause after smoking.
The researchers emphasized that these findings aim to help governments and health institutions in various countries in developing more specific prevention strategies. Instead of using a uniform approach, health policies are expected to focus on the greatest risk factors in each region to significantly reduce the burden of cancer in the future.
By controlling lifestyle and increasing access to vaccination against certain infections, millions of people could potentially avoid a cancer diagnosis in the future.
date:2026-02-07 13:03:00
Worth a look
- Ask Your Medical Science Questions to NPR
- 2026 Chuseok Subsidy: How to Claim Up to 500,000 KRW in Your Local Area
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)